27 juni 2012: Onderaan hebben we het abstract van onderstaande studie geplaatst plus een link naar een gratis in te zien volledig studierapport.

11 juni 2007: Bron: Eurokalert
Contact: Nancy Stringer-Nstringer@ucsd.edu- 619-543-6163
University of California - San Diego

CHICAGO, June 4, 2007 -- Vrouwen die voor hun borstkanker Tamoxifen gebruiken maar daarnaast ook regelmatig last hebben van opvliegers blijken beduidend minder kans op een recidief te hebben (12,9% tegenover 21%) dan vrouwen die geen of minder opvliegers hebben tijdens hun Tamoxifen behandeling. Het verschil was zelfs zo groot dat die groter was dan de prognose op een recidief op basis van leeftijd, hormoonreceptor stadium en zelfs hoe gevorderd de borstkanker was op het moment van de diagnose. Aldus een gerandomiseerde jarenlange studie in meerdere ziekenhuizen en centraal geleid door de Moores Cancer Center of the University of California, San Diego (UCSD). Van de 1,551 vrouwen met borstkanker gediagnosteerd en behandeld in een vroeg stadium, en die gelijk werden gerandomiseerd in twee groepen binnen de WHEL studie gebruikte meer dan de helft Tamoxifen (864 vrouwen = 56%) en meer dan 2/3 (674 = 78%) van deze vrouwen rapporteerde regelmatig last te hebben van opvliegers.

De kans op een recidief dus terugkeer van de borstkanker onder vrouwen die opvliegers rapporteerden was ca. 12,9% tegenover 21% voor de vrouwen die geen opvliegers rapporteerden. Een significant en groot verschil dus. Wat het betekent voor vrouwen die opvliegers tegengaan door allerlei middelen en medicijnen staat niet in dit persbericht vermeld. Wellicht wel in het volledige studierapport welke is gepresenteerd op ASCO 2007. We zullen proberen dat volledige studieverslag te pakken te krijgen.

CHICAGO, June 4, 2007 -- Women on tamoxifen therapy who reported having hot flashes were less likely to develop recurrent breast cancer than those who did not report hot flashes, according to a study from the Moores Cancer Center at the University of California, San Diego (UCSD). Moreover, hot flashes were a stronger predictor of outcome than age, hormone receptor status or even how advanced the breast cancer was at diagnosis.

The study results were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago today.

"Hot flashes are a very common and disruptive problem in breast cancer survivors," said the study's first author Joanne Mortimer, M.D., medical director of the Moores Cancer Center and professor of medicine with the UCSD School of Medicine. "About two-thirds of women with breast cancer say hot flashes compromise their quality of life. The most common request for additional treatment we get is for relief from these symptoms."

The study was based upon data from the comparison group of the Women's Healthy Eating and Living (WHEL) study ? a multi-site randomized trial of the impact of a diet high in vegetables, fruits and fiber, and low in fat on the recurrence of breast cancer. The WHEL participating institutions are University of California, San Diego and Davis, Stanford University, Kaiser Permanente in Oakland and Portland, University of Arizona at Tucson, and the University of Texas MD Anderson Cancer Center in Houston.

Of the 1,551 women with early-stage breast cancer who were randomized to the comparison group of the WHEL study, more than half (864, or 56 percent) were taking tamoxifen, and more than three-quarters of those (674, or 78 percent) reported hot flashes.

Cancer recurrence among women who reported hot flashes was about 12.9 percent, compared with 21 percent for women not reporting hot flashes. These data were consistent across all years of follow-up, regardless of age or menopausal status.

"This study provides the first evidence that hot flashes may be an indicator of a better prognosis in women with early stage breast cancer," said the study's senior author, John P. Pierce, Ph.D, director of the Cancer Prevention and Control Program at the Moores UCSD Cancer Center. "Our data support the possibility of a significant association between hot flashes and disease outcome."

As a next step, the researchers plan to further study the relationship between hot flashes and breast cancer progression by measuring the tamoxifen metabolites in breast cancer survivors.

### Besides Mortimer and Pierce, authors on the paper are Shirley W. Flatt, M.S., Barbara A. Parker, M.D., Linda Wasserman, M.D., Ph.D., and Loki Natarajan, Ph.D., of the Cancer Prevention and Control Program, Moores UCSD Cancer Center; and Ellen B. Gold of the Department of Public Health Sciences at University of California, Davis. This work was supported by the Walton Family Foundation and a National Cancer Institute grant.

Founded in 1979, the Moores UCSD Cancer Center is one of just 40 centers in the United States to hold a National Cancer Institute (NCI) designation as a Comprehensive Cancer Center. As such, it ranks among the top centers in the nation conducting basic, translational and clinical cancer research, providing advanced patient care and serving the community through innovative outreach and education programs.

Hot flashes were a stronger predictor of breast cancer specific outcome than age, hormone receptor status, or even the difference in the stage of the cancer at diagnosis

Source: Breast Cancer Res Treat. Author manuscript; available in PMC 2009 April 1.

Published in final edited form as:
Published online 2007 May 31. doi:  10.1007/s10549-007-9612-x

Tamoxifen, hot flashes and recurrence in breast cancer.

Source

Cancer Prevention and Control Program, Moores UCSD Cancer Center, University of California, San Diego, La Jolla, CA 92093-0901, USA.

Abstract

We utilized data from the comparison group of the Women's Healthy Eating and Living randomized trial to investigate an "a priori" hypothesis suggested by CYP2D6 studies that hot flashes may be an independent predictor of tamoxifen efficacy. A total of 1551 women with early stage breast cancer were enrolled and randomized to the comparison group of the WHEL multi-institutional trial between 1995 and 2000. Their primary breast cancer diagnoses were between 1991 and 2000. At study entry, 864 (56%) of these women were taking tamoxifen, and hot flashes were reported by 674 (78%). After 7.3 years of follow-up, 127 of those who took tamoxifen at baseline had a confirmed breast cancer recurrence. Women who reported hot flashes at baseline were less likely to develop recurrent breast cancer than those who did not report hot flashes (12.9% vs 21%, P = 0.01). Hot flashes were a stronger predictor of breast cancer specific outcome than age, hormone receptor status, or even the difference in the stage of the cancer at diagnosis (Stage I versus Stage II). These findings suggest an association between side effects, efficacy, and tamoxifen metabolism. The strength of this finding suggests that further study of the relationship between hot flashes and breast cancer progression is warranted. Additional work is warranted to clarify the mechanism of hot flashes in this setting.

PMID:
17541741
[PubMed - indexed for MEDLINE]

PMCID:
PMC2575100

Read more>>>>>>>




Plaats een reactie ...

Reageer op "Opvliegers tijdens ziekte blijken betere prognose op genezing van borstkanker te geven en geven bijna 50 procent minder kans op een recidief. 12,9 procent tegenover 21 procent.."


Gerelateerde artikelen
 

Gerelateerde artikelen

Studiepublicaties van niet-toxische >> Sonia studie: Borstkanker >> Recente studiepublicaties >> Algemeen: Borstkanker korte >> Arimidex - anastrozole informatie >> Arimidex: 2 jaar aromataseremmers >> Artemisinin - Armesia: informatie >> Avastin in combinatie met >> Bestraling bij borstkanker: >> Bisfosphonaten zoals Zometa >>